Chimeric Antigen Receptor (CAR) T Cell Generation for Therapeutic Testing in the Disseminated NALM6-Luc Human B-Cell Acute Lymphoblastic Leukemia Model
AACR 2022 -- T cells engineered to express Chimeric Antigen Receptors (CARs) through transduction with a lentiviral vector represent an effective strategy to specifically eliminate cancerous cells from a patient. Anti-CD19 single chain variable fragment (ScFv) is the extracellular, antigen-binding domain. The intracellular portion of the CAR is derived from 4-1-BB and CD3ζ. Our lab produced a CD19-targeted CAR T cell tool therapy to support preclinical combination strategies for development of assets to be used in concert with cell therapy.